Overview: Cancer Antigen 19-9 TestIntroduction: The Cancer Antigen 19-9 Test measures CA 19-9, a cancer marker to monitor pancreatic cancer, causing abdominal pain or jaundice. Aligned with 2023 NCCN guidelines, it uses an immunoassay for high sensitivity, aiding in cancer screening. This test is critical for guiding treatment monitoring, assessing disease progression, and improving outcomes in immunology for patients with suspected pancreatic cancer.
Other Names: CA 19-9 Assay, Pancreatic Cancer Marker Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: CA 19-9 testing began in the 1980s with pancreatic cancer research. Immunoassays emerged in the 1990s, and by the 2000s, high-sensitivity assays improved monitoring accuracy.
Purpose: Monitors pancreatic cancer, guides treatment, and assesses disease progression in patients with abdominal pain or jaundice.
Test Parameters: 1. CA 19.9
Pretest Condition: No fasting required. Collect serum at any time. Report symptoms like abdominal pain or jaundice, and list medications like chemotherapy.
Specimen: 2-5 mL serum (SST). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document abdominal pain, jaundice, or family history of pancreatic cancer. Include current medications, especially chemotherapy or targeted therapies.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for cancer treatment.
Procedural Considerations: Uses an immunoassay to measure CA 19-9 levels. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Benign conditions like pancreatitis may elevate CA 19-9 levels. Hemolysis or improper storage can degrade samples.
Clinical Significance: Elevated CA 19-9 levels indicate pancreatic cancer progression, prompting chemotherapy or surgery. Normal levels suggest stable disease or remission.
Specialist Consultation: Consult an oncologist for result interpretation. A gastroenterologist referral is advised for pancreatic cases.
Additional Supporting Tests: Abdominal CT, CEA test, or endoscopic ultrasound to confirm pancreatic cancer or assess disease extent.
Test Limitations: False positives may occur with benign pancreatic conditions. Results require clinical correlation with imaging.
References: NCCN Pancreatic Cancer Guidelines, 2023; Journal of Clinical Oncology, Tempero MA, 2022.
